Nonsteroidal antiinflammatory drugs and the kidney;Nesteroidní antirevmatika a ledviny

Vnitrni Lekarstvi

Volumn 52, Issue 7-8, 2006, Pages 686-690

  Zadrazil J ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Acute intestitial nephritis; Acute renal failure; Chronic renal insufficiency; Hyperkalemia; Hyponatremia; Nephrotic syndrome; Nonsteroidal antiiflammatory drugs; Papillary necrosis; Prostaglandins; Water retention

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; RENIN;

ACUTE KIDNEY FAILURE; ARTICLE; CHRONIC KIDNEY FAILURE; EDEMA; HENLE LOOP; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY; KIDNEY ISCHEMIA; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; RENIN RELEASE; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SODIUM ABSORPTION; SODIUM RETENTION; VASCULAR RESISTANCE; WATER ABSORPTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; KIDNEY; KIDNEY DISEASES; WATER-ELECTROLYTE IMBALANCE;

EID: 33747766169     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.
2. FitzGerald GA. The choreography of cyclooxygenases in the kidney. J Clin Invest 2002; 110: 33-34.
3. Diaz-Gonzalez F, Gonzalez-Alvaro I, Campanero MR et al. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs. J Clin Invest 1995; 95: 1756-1765.
4. Amin AR, Vyas P, Attur M et al. The mode of action of aspirin like-drugs: Effect on inducible nitric oxide synthetase. Proc Natl Acad Sci USA 1995; 92: 1926-1930.
5. Huerta C, Castellsague J, Varas-Lorenzo C et al. Nonsteroidal antiinflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45: 531-539.
6. Horáčková M. Analgetika a ledviny. Vztah hodnocený klinickým nefrologem. Praha: Triton 2000.
7. Whelton A, Stout RL, Spilman PS et al. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison. Ann Intern Med 1990; 112: 568-576.
8. Braden GL, O'Shea MH, Mulhern JG et al. Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors. Nephrol Dial Transplant 2004; 19: 1149-1153.
9. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001; 111: 64-67.
10. Baker RL, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant 2004; 19: 8-11.
11. Alper AB jr, Meleg-Smith S, Krane NK. Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 2002; 40: 1086-1090.
12. Esteve JB, Launay-Vacher V, Brocheriou I et al. COX-2 inhibitors and acute interstitial nephritis: Case report and review of the literature. Clin Nephrol 2005; 63: 385-389.
13. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int 2001; 60: 804-817.
14. Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int 1989; 35: 1257-1270.
15. Clarkson MR, Giblin L, O'Connell FP et al. Acute interstitial nephritis: Clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 2004; 19: 2778-2783.
16. Warren GV, Korbet SM, Schwartz MM et al. Minimal change glomerulopathy associated with nonsteroidal antiinflammatory drugs. Am J Kidney Dis 1989; 13: 127-130.
17. Campistol JM, Galofre J, Botey A et al. Reversible membranous nephritis associated with diclofenac. Nephrol Dial Transplant 1989; 4: 393-395.
18. Radford MG, Holley KE, Grande JP et al. Reversible membranous nephropathy associated with the use of nonsteroidal antiinflammatory drugs. JAMA 1996; 276: 466-469.
19. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993; 44: 643-653.
20. Kramer HJ, Glanzer K, Dusing R. Role of prostaglandins in the regulation of renal water excretion. Kidney Int 1981; 19: 851-859.
21. Hebert RL, Carmosino M, Saito O et al. Characterization of rabbit kidney prostaglandin F (2 alpha) receptor exhibiting G(i)-restricted signaling that inhibits water absorption in the collecting duct. J Biol Chem 2005; 280: 35028-35037.
22. Satoh T, Cohen HT, Katz AI. Intracellular signalling in the regulation of renal Na-K-ATPase. Role of cyclic AMP and phospholipase A2. J Clin Invest 1992; 89: 1496-1500.
23. Gunning ME, Brady HR, Otuechere G et al. Atrial natriuretic peptide (31-67) inhibits Na+ transport in rabbit inner medullary collecting duct. Role of prostaglandin E2. J Clin Invest 1992; 89: 1411-1417.
24. Oates JA, FitzGerald GA, Branch RA et al. Clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med 1988; 319: 761-767.
25. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002; 32 (Suppl 1): 33-42.
26. Clark BA, Shannon RP, Rosa RM et al. Increased susceptibility to thiazide-induced hyponatremia in the elderly. J Am Soc Nephrol 1994; 5: 1106-1111.
27. Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med 2002; 69 (Suppl 1): 153-158.
28. Fu Q, Zhang R, Witkowski S et al. Persistent sympathetic activation during chronic antihypertensive therapy: a potential mechanism for long term morbidity? Hypertension 2005; 45: 513-521.
29. Pope JE. Hypertension, NSAID, and lessons learned. J Rheumatol 2004; 31: 1143-1151.
30. Sowers JR, White WB, Pitt B et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal antiinflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 161-168.
31. Fogari R, Zoppi A, Carretta R et al. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: A multicentre study. J Hypertens 2002; 20: 1007-1014.
32. Aw TJ, Haas SJ, Liew D et al. Metaanalysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490-496.
33. Klassen DK, Jane LH, Young DY et al. Assessment of blood pressure during naproxen therapy in hypertensive patient treated with nicardipine. Am J Hypertens 1995; 8: 146-153.
34. Bennett WM, Porter GA. Analgesic nephropathy and the use of nonsteroidal antiiflammatory drugs in renal patients: New insights. J Nephrol 1998; 11: 70-75.
35. Akhund L, Quinet RJ, Ishaq S. Celecoxib - related renal papillary necrosis. Arch Intern Med 2003; 163: 114-115.
36. Safirstein R. Gene expression in nephrotoxic and ischemic acute renal failure. J Am Soc Nephrol 1994; 4: 1387-1395.
37. Gault MH, Garrett BJ. Analgesic nephropathy. Am J Kidney Dis 1998; 32: 351-360.
38. Segasothy M, Samad S, Zulfigar A et al. Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis 1994; 24: 17-24.
39. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal antiinflammatory drugs: Summary and recommendations. Am J Kidney Dis 1996; 28 (Suppl 1): 56-62.
40. Kurth T, Glynn RJ, Walker AM et al. Analgesic use and change in kidney function in apparently healthy men. Am J. Kidny Dis 2003; 42: 234-244.
41. De Broe ME, Elsevier MM. Analgesic nephropathy. N Engl J Med 1998; 338: 446-452.
42. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nosteroidal antiiflammatory drugs. N Engl J Med 1994; 331: 1675-1679.
43. Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 2005; 11: 1795-1804.